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Background: The purpose of this study was to investigate the long-term effects of adalimumab, 
a tumor necrosis factor alpha antagonist, in the treatment of uveitis associated with juvenile 
idiopathic arthritis.
Methods: Adalimumab was initiated in 94 patients with juvenile idiopathic arthritis to treat 
active arthritis and/or active associated uveitis. In 18 patients, therapy was discontinued after 
a short period because of inefficacy or side effects. The activity of uveitis (using Standardized 
Uveitis Nomenclature [SUN] criteria and clinical examination) and arthritis (number of swollen 
or active joints) was evaluated at the start and at end of the study.
Results: At the end of the study, uveitis was under good clinical control in two thirds of 
54 patients (31% did not need any local treatment and 35% used only 1–2 corticosteroid drops 
a day), and one third had active uveitis (at least three corticosteroid drops a day). According to 
SUN criteria, adalimumab treatment for uveitis showed improved activity (a two-fold decrease 
in uveitis activity) in 28% of patients, with a moderate response in 16 patients, no change in a 
further 16 patients, and worsening activity (a two-fold increase in uveitis activity) in 13% of 
patients. The overall proportion of patients with active arthritis decreased. At the beginning of 
the study, 69% of patients with uveitis had more than two active joints, and at the end of the 
study only 27% had active joint disease. In 27 patients with juvenile idiopathic arthritis with-
out uveitis on adalimumab, the number of active joints decreased from 93% to 59%. Systemic 
corticosteroid treatment could be stopped in 22% of patients with uveitis and in 11% of those 
without uveitis. Most of the patients had received methotrexate, other immunosuppressive 
therapy, or other biological drugs before initiating adalimumab.
Conclusion: Adalimumab is a valuable option in the treatment of uveitis associated with active 
juvenile idiopathic arthritis.
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Introduction
Anterior uveitis is a serious manifestation of juvenile idiopathic arthritis, with a 
potential for significant ocular damage and even blindness. Uveitis has been reported 
in 10%–20% of patients with juvenile idiopathic arthritis, although lower and higher 
figures have been published.1,2 Antinuclear antibody (ANA)-positive girls younger than 
seven years of age with oligoarthritis are at the greatest risk of developing uveitis.2
The first-line standard therapy for uveitis is topical and systemic corticosteroids, 
often reinforced by methotrexate as a second-line disease-modifying antirheumatic drug 
(DMARD). Tumor necrosis factor-alpha (TNF-α) has been shown to play an important 
role in the development of uveitis.3 TNF-α blockers have been used to treat uveitis and 
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juvenile idiopathic arthritis, and especially uveitis associated 
with juvenile idiopathic arthritis in children who have failed 
conventional topical and second-line DMARD therapy.4,5 
A meta-analysis of the impact of anti-TNF therapy on anterior 
uveitis in ankylosing spondylitis was used to compare the 
effect of infliximab and etanercept to decrease the number 
of uveitis flares in 717 patients with ankylosing spondylitis. 
The flares were less frequent during infliximab than   
  during etanercept treatment.6 A Canadian study   compared 
the efficacy of etanercept and infliximab in uveitis among 
21 patients with active uveitis at onset of treatment. A better 
clinical response with fewer ocular complications was seen 
with infliximab than etanercept.7
In a small study from Columbia, ocular inflammation in 
13 of 14 children responded to adalimumab (a humanized 
monoclonal TNF-α antibody).8 A better effect of   adalimumab 
for uveitis compared with etanercept was shown in a   German 
study of 18 children and young adults with juvenile uveitis 
and/or arthritis.9,10 In a Finnish retrospective study, of 
20 patients with juvenile idiopathic arthritis and chronic uveitis 
on adalimumab treatment, seven (35%) showed improved 
activity, one (5%) had worsening activity, and 12 (60%) 
showed no change.11 A recent Greek study reported a decrease 
in uveitis flares with adalimumab treatment in three of 
six patients with juvenile idiopathic arthritis and uveitis.12 
We describe a large retrospective cohort of patients with 
juvenile idiopathic arthritis and associated uveitis treated with 
adalimumab for a mean of two years.
Patients and methods
This study was based on data for 320 patients drawn from 
the juvenile idiopathic arthritis registry for biologic drugs 
at the Rheumatism Foundation Hospital, Heinola, Finland, 
for 2008–2010. Some of these cases belonged to the cohort 
described earlier by Tynjälä et al.11 From the patient records, 
we collected baseline demographic data (age, gender, age 
at disease onset, duration of disease), disease information 
(juvenile idiopathic arthritis subtype, number of active joints, 
laboratory values, if available), and treatment data (biologics 
and concomitant DMARDs, including start and stop dates, as 
well as reasons for withdrawal). The study was retrospective 
and evaluated the long-term impact of adalimumab, the 
monoclonal anti-TNF-α antibody, on juvenile idiopathic 
arthritis and associated uveitis.
The 2001 revised International League Against 
Rheumatism classification criteria for juvenile idiopathic 
arthritis were used in this study.13 All diagnoses of juvenile idio-
pathic arthritis were confirmed by a pediatric rheumatologist   
who examined arthritis activity by evaluating the number 
of swollen or active joints and joints with a limited range 
of motion at the start of adalimumab therapy and at the end 
of the study. Inflammatory laboratory markers (erythocyte 
sedimentation rate and C-reactive protein), if available, were 
recorded.
Evaluation of the efficacy of adalimumab on uveitis activity 
was done using the Standardized Uveitis Nomenclature (SUN) 
criteria (a two-fold improvement or a two-fold worsening of 
uveitis, ie, a change in the amount of anterior chamber cells 
and flare) and clinical examination (evaluating the decrease 
in activity of inflammation in the eye by biomicroscopy, 
decrease in amount of anterior chamber cells and flare, and 
decrease in amount of topical treatment).14
Remission of juvenile idiopathic arthritis with medication 
was stated if the patient had no joints with active arthritis and 
no systemic signs (eg, fever, rash). Erythocyte sedimentation 
rate and C-reactive protein needed to be at normal levels. No 
global assessment of disease activity scores was available in 
this retrospective series.15
The clinical response to treatment for uveitis was 
considered good if there were ,3 anterior chamber 
cells/1 mm slit and there was no need for corticosteroid 
drops. A   moderate response was deemed to be 3–9 ante-
rior chamber cells/1 mm slit and no more than three 
corticosteroid drops per day. Ineffective treatment was con-
sidered to be .10 cells in the anterior chamber and more 
than three corticosteroid drops per day (beyond which the 
risk of cataract is increased).
Adalimumab was initiated in 94 patients with juvenile 
idiopathic arthritis because of active arthritis and/or active 
associated uveitis. The patients were divided into two groups, 
ie, 54 patients with juvenile idiopathic arthritis and uveitis 
and 40 patients with juvenile idiopathic arthritis and without 
uveitis.
The 54 patients with uveitis were either not responsive 
to standard immunosuppressive therapy for uveitis or were 
intolerant to it. Adalimumab was administered at a dose of 
24 mg/m2 at 14-day intervals subcutaneously, and accord-
ing to clinical response, up to a frequency of 24 mg/m2 at 
seven-day intervals. In 22 patients with uveitis, adalimumab 
was the first anti-TNF treatment and was started because of 
active ocular inflammation.
The results are expressed as the median ± standard 
deviation and interquartile range. Statistically significant 
differences between the groups were evaluated using the 
Mann–Whitney U test and Chi-squared and Fisher Exact 
tests, as appropriate.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Results
The main characteristics of the 94 patients receiving 
adalimumab at the beginning of the study are shown in 
Table 1. The number of girls was slightly higher among the 
patients with uveitis (69%) than those without it (65%). The 
median age at onset of arthritis was lower in the patients 
with uveitis (median 3.0 years, interquartile range 2–7 years) 
than that of patients without uveitis (median 5.0 years, 
interquartile range 3–11 years), but the difference was not 
statistically significant. Patients with uveitis were more often 
ANA-positive (P , 0.001).
The majority of patients with uveitis had oligoarthritis 
(26%) or extended oligoarthritis (31%). Among the patients 
without uveitis, the arthritis subtype was more aggressive; 
one patient had oligoarthritis, 12 had extended oligoarthritis, 
22 had seronegative polyarthritis, two had seropositive 
polyarthritis, two had systemic onset arthritis, and one had 
spondyloarthropathy.
Adalimumab was stopped in 18 patients (five with 
associated uveitis) after a short period because of inefficacy or 
side effects, except for one patient who went to remission. At 
the end of the study, uveitis was under good clinical control 
in two thirds of patients, ie, 31% did not need any local 
treatment for uveitis and 35% used only 1–2 corticosteroid 
drops per day. One third of the patients still had active uveitis 
and used at least three corticosteroid drops per day.
According to the SUN criteria, the response to adalimumab 
treatment was improved in 28% of patients, and worsened 
(two-step change in the amount of inflammation in the 
anterior chamber) in 13% of patients (Tables 2 and 3).   Taking 
into account the 16 patients with uveitis whose response 
to adalimumab was moderate, an overall positive effect of 
adalimumab was seen in 57% of the patients with uveitis.
After 24 months of treatment with adalimumab, the pro-
portion of patients with active arthritis decreased from 69% to 
27% in the patients with uveitis, and from 93% to 59% in 
those without uveitis (Table 4). Systemic corticosteroid 
treatment could be stopped in 22% of patients with uveitis 
and in 11% of those without uveitis (P = 0.222, data not 
shown).
Binocular visual acuity in the patients with juvenile 
idiopathic arthritis and uveitis was good in all but one 
patient who was legally blind because of severe early-onset 
chronic uveitis associated with juvenile psoriatic arthritis. 
Twenty-eight children (52%) with juvenile idiopathic arthritis 
developed complications of uveitis, comprising five children 
who had incipient cataract, 21 who had undergone cataract 
surgery (intraocular lens implantation in 20 cases), five with 
Table 1 Demographics of 94 patients with juvenile idiopathic arthritis receiving adalimumab
Variable JIA with uveitis 
(n = 54)
JIA without uveitis 
(n = 40)
P value
Female, n (%) 37 (69) 26 (65) 0.72
Age at diagnosis, years, median (iQr) 3 (2, 7) 5 (3, 11) 0.027
Age at end of study, years, median (iQr) 15 (14, 18) 16 (11, 18) 0.67
Course type of arthritis, n (%) 0.003
  Oligoarthritis 14 (26) 1 (2)
  extended oligoarthritis 17 (31) 12 (30)
  Polyarthritis: 20 (27) 24 (60)
  seronegative 20 22
  systemic JiA 0 (0) 2 (5)
  Psoriatic arthritis 2 (4) 0 (0)
  spondyloarthropathy 1 (2) 1 (2)
hLA B27 present n (%)† 12 (32) 13 (50) 0.16
AnA present n (%)‡ 36 (71) 9 (31) ,0.001
Notes: †15 patients with uveitis and 2 without uveitis were missing data for hLA-B27; ‡1 patient with uveitis and 3 without uveitis were missing data for the AnA studies. 
Abbreviations: AnA, antinuclear antibody; hLA, human leukocyte antigen; iQr, interquartile range; JiA, juvenile idiopathic arthritis.
Table 2 Clinical control of uveitis in 54 patients treated with 
adalimumab
Effect of treatment on local uveitis Patients 
n (%)
no corticosteroid drops 17 (31)
1–2 corticosteroid drops/day 19 (35)
$3 corticosteroid drops/day 18 (33)
Table 3 Efficacy on uveitis according to Standardized Uveitis 
nomenclature criteria in 54 patients*
Response to treatment Patients, n (%)
improved activity 15 (28)
Moderate response 16 (30)
no change 16 (30)
Worsening activity 7 (13)
Note: *Adalimumab was stopped in 5 patients.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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secondary glaucoma (Molteno implantation in three), and 
three with uveitis complicated by cystoid macular edema.
Most of the patients had been previously treated with 
more than one DMARD as monotherapy or as part of 
combination therapy (methotrexate, hydroxychloroquine, 
leflunomide, sulfasalazine, cyclosporin A, mycophenolate 
mofetil). At the end of the study, only four of 54 patients 
with juvenile idiopathic arthritis and uveitis remained on 
adalimumab monotherapy, and the rest were on combination 
therapy with prednisolone (n = 9), methotrexate (n = 34), 
leflunomide (n = 9), cyclosporin A (n = 7), azathioprine 
(n = 1), sulfasalazine (n = 4), or hydroxychloroquine 
(n = 2). The numbers of patients with uveitis on an anti-
metabolite and on systemic steroids at baseline and at the 
end of the study are shown in Table 5. Prednisolone therapy 
could be stopped in 22% of patients with uveitis. Of these 
patients, 29 had not responded to previous anti-TNF agents 
(etanercept or infliximab). Twenty-five patients were receiv-
ing adalimumab every fortnight at the end of the study, and 
24 patients were receiving it weekly. The main clinical reason 
for weekly treatment was activity of uveitis.
Discussion
Adalimumab is a valuable option in the treatment of uveitis 
associated with refractory juvenile idiopathic arthritis. Our study 
was retrospective, but is one of the largest done in patients with 
treatment-resistant childhood uveitis treated with adalimumab. 
At the end of this study, disease activity improved in 15 of 
54 patients with uveitis on adalimumab therapy (31% of those 
continuing with adalimumab), and disease activity worsened 
in seven patients (13%) according to SUN criteria. However, 
improvement of uveitis was seen altogether in 31 out of 
54 patients (57%), because in another 16 patients with uveitis 
the response for uveitis was moderate, but did not reach the two-
fold change. In 16 cases, no change was seen according to SUN 
criteria. Clinical evaluation gave better results (improvement of 
uveitis in 66% of patients), because the use of SUN criteria in 
the evaluation of juvenile idiopathic arthritis-associated uveitis 
is difficult. The amount of anterior chamber cells is often quite 
small when the eye disease is still active. The two-fold difference 
is hard to achieve, because changes are quite small. In many 
cases, clinical evaluation by an experienced ophthalmologist 
may be better. The rate of favorable outcome was somewhat 
higher in previous studies with smaller numbers of patients, 
in which the activity of uveitis improved in 35% (seven of 
20 patients) according to a report by Tynjälä et al and in 89% 
according to a report by Biester et al.9,11
The type of arthritis was more severe in patients without 
uveitis. Any significant risk factors according to the type of 
arthritis were noted in this study. Both persistent and extended 
oligoarthritis groups were equally represented among the 
patients with juvenile idiopathic arthritis associated with 
uveitis. Interestingly, in a study from the UK consisting of 
23 patients with juvenile idiopathic arthritis and uveitis, an 
association between patients with extended oligoarthritis and 
uveitis was noted, and patients with extended oligoarthritis 
also had a shorter interval from diagnosis of arthritis to devel-
opment of uveitis.16 Five patients with juvenile idiopathic 
arthritis and uveitis had discontinued adalimumab therapy 
due to adverse events or inefficacy.
Our study was performed in clinical practice conditions, 
with a long period of follow-up by one ophthalmologist. 
Adalimumab was a good option in the treatment of patients 
with juvenile idiopathic arthritis and associated uveitis, often 
in combination with methotrexate and/or other DMARDs.
Disclosure
The authors report no conflicts of interest in this work.
Table 4 effect of adalimumab on arthritis, and number of patients on adalimumab therapy at end of study
Patients on adalimumab therapy at end of study  
with signs of inflammation and swollen/active joints
Patients with uveitis 
(n = 49)
Patients without uveitis 
(n = 27)
P value
At start of adalimumab, n (%) 34 (69) 25 (93) 0.023
At end of study 13 (27) 16 (59) 0.005
Table 5 number of patients with uveitis on an antimetabolite 
and systemic steroids at baseline and at end of study
Treatment at  
baseline in patients  
with uveitis 
(n = 54)
Treatment at  
end of study 
JIA with uveitis 
(n = 54)
Prednisolone 20 9
Methotrexate 47 34
hydroxychloroquine 5 2
Cyclosporin A 10 7
Azathioprine 2 1
Leflunomide 13 9
Sulfasalazine 8 4
Abbreviation: JiA, juvenile idiopathic arthritis.Clinical Ophthalmology
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